🧬Tidera Health
⚕️

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

OncologyICD-10: C64

Find Recruiting Clinical Trials for Kidney Cancer

Search RCC, clear cell, non-clear cell, and adjuvant kidney cancer trials — matched to your histology, IMDC risk, and prior therapy.

🔍 Search Kidney Cancer Trials →

About Kidney Cancer

Renal cell carcinoma (RCC) is the most common type of kidney cancer, representing 90% of cases. Clear cell RCC (ccRCC) is the most prevalent histology (70–80%) and is driven by VHL gene alterations. Treatment has been transformed by immune checkpoint inhibitor combinations (nivolumab + ipilimumab, pembrolizumab + axitinib, nivolumab + cabozantinib) and VEGFR TKI monotherapy. While these combinations have achieved durable responses in a subset of patients, the majority eventually develop resistance, and non-clear cell RCC subtypes (papillary, chromophobe, collecting duct) remain significantly undertreated.

What Types of Kidney Cancer Clinical Trials Exist?

RCC trials are active across all disease stages. Adjuvant trials test checkpoint inhibitors (pembrolizumab adjuvant) and TKIs (sunitinib, pazopanib) after nephrectomy. First-line metastatic trials test novel IO/TKI combinations and triplet regimens. Resistance trials test VEGF-independent approaches, HIF-2α inhibitors (belzutifan for VHL-mutant/clear cell RCC), and next-generation immunotherapy. IMDC risk category (favorable vs. intermediate/poor), VHL/HIF-2α pathway alterations, PD-L1 expression, and prior TKI/IO history determine eligibility.

Find Recruiting Kidney Cancer Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time — matching trials to your age, location, and treatment history. Free, no account required.

Search Kidney Cancer Trials →

Data from ClinicalTrials.gov · Updated in real time · Educational use only

Frequently Asked Questions

What clinical trials are available for kidney cancer?▾
Recruiting RCC trials include HIF-2α inhibitor combinations (belzutifan-based), novel IO combinations (LAG-3, TIM-3 checkpoint inhibitors), VEGFR TKI + IO triplets, CAR-T and TIL therapies, antibody-drug conjugates, and post-IO resistance trials. Non-clear cell RCC (papillary, chromophobe, collecting duct) has dedicated trial programs.
What is IMDC risk score and how does it affect RCC trials?▾
IMDC (International Metastatic RCC Database Consortium) risk score uses 6 clinical factors (time from diagnosis, performance status, hemoglobin, neutrophil count, platelet count, calcium) to classify patients into favorable (0 factors), intermediate (1–2 factors), or poor (3–6 factors) risk groups. Most first-line combination trials stratify by IMDC risk, and some specifically enroll intermediate/poor risk patients for highest-risk interventions.
How does VHL mutation status affect RCC trial eligibility?▾
VHL gene inactivation is present in approximately 90% of clear cell RCC, leading to HIF-2α accumulation and activation of angiogenesis. Belzutifan (HIF-2α inhibitor) is FDA-approved for VHL disease-related tumors and is in trials for sporadic VHL-mutant clear cell RCC. VHL mutation testing (on tumor tissue) is required for HIF-2α-targeted trials. Patients with VHL disease (hereditary) have additional trial options.

Related Conditions

Bladder CancerLung CancerMelanoma

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.